From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
ComplementC5-IN-1 (Compound 7) is a small-molecule inhibitor of complement component 5 protein (C5).ComplementC5-IN-1 interacts with C5 to prevent its cleavage by the C5 convertase and blocks zymosan-induced the membrane-attack complex (MAC) deposition in 50% human whole blood with an IC50 of 0.77 µM .
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complementC5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research .
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .
Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .
Avacincaptad pegol, which is a pegylated aptamer, has garnered significant attention as a C5complement inhibitor that may reduce inflammation-related retinal pigment epithelium (RPE) damage. Avacincaptad pegol caqn be used for the research of stargardt macular dystrophy (STGD1) and geographic atrophy (GA) .
Avacincaptad pegol (ARC1905) is an anti-C5 RNA aptamer that inhibits the cleavage of complement factor 5 (C5) into C5a and C5b. Avacincaptad pegol is being used for the study of age-related macular degeneration (AMD).
Cemdisiran is an N-acetylgalactosamine (GalNAc) conjugated siRNA for the research of complement-mediated diseases by suppressing liver production of complement 5 (C5) protein.
Zilucoplan (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan can be used in research of immune-mediated necrotising myopathy (IMNM) .
Zilucoplan TFA (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan TFA can be used in research of immune-mediated necrotising myopathy (IMNM) .
Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction .
NH2-C6-ARC186 sodium is a modified ARC186 (HY-153098) with NH2-C6 that can be coupled to other peptides or molecules. ARC186 is a aptamer and a highly potent complement inhibitor that function by blocking the convertase-catalyzed activation of C5 .
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complementC5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .
Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (Ki=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus .
Triantennary GalNAc-1 is a triantennary N-acetylgalactosamine (GalNAc) that can be conjugated to the 3' end of the sense strand of siRNA. GalNAc promotes targeted delivery of siRNA to liver cells both in vitro and in vivo [1].
C5a Receptor agonist, mouse, human is a biological active peptide. (This peptide is derived from the C-terminus of the chemokine, complement fragment 5 anaphylatoxin (C5a). This peptide functions as a C5a receptor agonist. C5a is a plasma protein involved in cellular inflammatory processes by inducing chemotaxis, degranulation of leukocytes, increased vascular permeability, and cytokine production. The cyclohexylalanine at position 5 is crucial to agonist function. Arg at the last position is of the d-isomer.)
Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc .
JPE-1375 is a complementC5a receptor 1(C5aR1) antagonist. JPE-1375 effectively inhibits polymorphonuclear leukocyte mobilization (EC50=6.9 µM) and reduces TNF levels (EC50=4.5 µM) in mice. JPE-1375 can be used in studies of autoimmune and inflammatory diseases .
JR14a is a potent thiophene antagonist of human complement C3a receptor. JR14a shows selectivity for the human C3a receptor over C5a receptor. JR14a can suppress C3aR-mediated inflammation .
PMX-53 (3D53) is a synthetic peptidic and a potent and orally active complementC5a receptor (CD88) antagonist with an IC50 of 20 nM. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. PMX-53 specifically binds to C5aR1 and does not bind to the second C5aR (C5L2) and C3aR. PMX-53 has anti-inflammatory, anticancer and antiatherosclerotic effects .
Zilucoplan (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan can be used in research of immune-mediated necrotising myopathy (IMNM) .
PMX-53 (3D53) is a synthetic peptidic and a potent and orally active complementC5a receptor (CD88) antagonist with an IC50 of 20 nM. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. PMX-53 specifically binds to C5aR1 and does not bind to the second C5aR (C5L2) and C3aR. PMX-53 has anti-inflammatory, anticancer and antiatherosclerotic effects .
Zilucoplan TFA (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan TFA can be used in research of immune-mediated necrotising myopathy (IMNM) .
C5aR1 antagonist peptide is a biological active peptide. (This linear peptide is derived from the C-terminus of the chemokine, complement fragment 5 anaphylatoxin (C5a). This peptide functions to inhibit C5a binding and function at human and rat C5a receptors. C5a is crucial to triggering cellular immune responses and its overexpression is involved in arthritis, Alzheimer’s disease, cystic fibrosis, systemic lupus erythematosus, and other immunoinflammatory diseases.)
C5a Receptor agonist, mouse, human is a biological active peptide. (This peptide is derived from the C-terminus of the chemokine, complement fragment 5 anaphylatoxin (C5a). This peptide functions as a C5a receptor agonist. C5a is a plasma protein involved in cellular inflammatory processes by inducing chemotaxis, degranulation of leukocytes, increased vascular permeability, and cytokine production. The cyclohexylalanine at position 5 is crucial to agonist function. Arg at the last position is of the d-isomer.)
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complementC5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research .
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .
Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .
Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction .
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complementC5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .
Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (Ki=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus .
Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc .
Activated by a C5 convertase, Complement C5 induces the assembly of C5-C9, forming the membrane attack complex. The transient C6 binding site on C5b is pivotal for lytic complex formation. C5 proteolytic degradation yields C5a anaphylatoxin, a local inflammatory mediator. Interacting with C5AR1, C5a induces diverse responses, including calcium release, muscle contraction, vascular permeability, and histamine release. As a potent chemokine, C5a guides leukocyte migration to inflammation sites, orchestrating immune responses. Complement C5/C5a Protein, Human (HEK293, His) is the recombinant human-derived Complement C5/C5a protein, expressed by HEK293, with C-His labeled tag. The total length of Complement C5/C5a Protein, Human (HEK293, His) is 1658 a.a., with molecular weight of 110-114 kDa (α chain) & 69-73 kDa (β chain), respectively.
Complement C5/C5a Protein, Mouse is a recombinant mouse complement component 5a (C5a). C5a is a potent pro-inflammatory mediator and acts as an essential part of the innate immune response.
Complement C5 is activated by C5 convertase, inducing C5-C9 assembly to form the membrane attack complex. The transient C6 binding site on C5b is critical for the formation of the cleavage complex. Complement C5/C5a Protein, Human (His) is the recombinant human-derived Complement C5/C5a protein, expressed by E. coli , with N-His labeled tag. The total length of Complement C5/C5a Protein, Human (His) is 74 a.a., with molecular weight of 13-14 kDa.
Complement C5/C5a Protein activates late complement components to form the membrane attack complex, C5-C9. C5b binds C6, initiating lytic complex assembly. C5a, produced by C5 degradation, acts as an anaphylatoxin, inducing local inflammation. C5a stimulates intracellular calcium release, smooth muscle contraction, vascular permeability, histamine release, and acts as a chemokine, guiding leukocyte migration. Complement C5/C5a Protein, Mouse (Biotinylated) is the recombinant mouse-derived Complement C5/C5a protein, expressed by E. coli, with tag free. The total length of Complement C5/C5a Protein, Mouse (Biotinylated) is 77 a.a., with molecular weight of ~9 KDa.
Complement C5/C5a Protein, a component of the complement system, is involved in the immune response and inflammation. It is cleaved to generate C5a, a potent pro-inflammatory mediator. Complement C5/C5a Protein's role in immune regulation and its potential as a therapeutic target make it a promising candidate for the treatment of inflammatory disorders and autoimmune diseases. Complement C5/C5a Protein, Pig (P.pastoris, His) is the recombinant pig-derived Complement C5/C5a protein, expressed by P. pastoris , with N-His labeled tag. The total length of Complement C5/C5a Protein, Pig (P.pastoris, His) is 74 a.a., with molecular weight of ~10.6 kDa.
Complement C5/C5a Protein, Human is a recombinant human complement C5a. C5a is a 74-amino acid glycoprotein generated on activation of the C system. Complement C5 is cleaved by proteolysis in the terminal phase of complement activation generating the pro-inflammatory C5a and membrane attack complex nucleator C5b. C5a is an inflammatory mediator generated by complement activation that positively regulates various arms of immune defense, including Toll-like receptor 4 (TLR4) signaling.
Complement C5 is activated by C5 convertase, inducing C5-C9 assembly to form the membrane attack complex. The transient C6 binding site on C5b is critical for the formation of the cleavage complex. Complement C5/C5a Protein, Cynomolgus is the recombinant cynomolgus-derived Complement C5/C5a protein, expressed by E. coli , with tag free. The total length of Complement C5/C5a Protein, Cynomolgus is 74 a.a., with molecular weight of ~11 kDa.
C5AR1 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays.
Complement C2 is a component of the classical pathway of the complement system and is cleaved by activated factor C1, resulting in the formation of two distinct fragments: C2b and C2a. The subsequent serine protease activity of C2a is critical for its subsequent interaction with the complement factor C4b, leading to the formation of C3 or C5 convertase. C2/Complement C2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived C2/Complement C2 protein, expressed by HEK293 , with C-His labeled tag. The total length of C2/Complement C2 Protein, Mouse (HEK293, His) is 760 a.a., with molecular weight of ~91.2 kDa.
C2/Complement C2 protein is essential in the classical pathway of the complement system. Activated by factor C1, C2 is cleaved into C2b and C2a. As a serine protease, C2a interacts with C4b, generating the C3 or C5 convertase. This crucial process activates and amplifies the complement cascade. C2/Complement C2 Protein, Human (HEK293, His) is the recombinant human-derived C2/Complement C2 protein, expressed by HEK293 , with C-His labeled tag. The total length of C2/Complement C2 Protein, Human (HEK293, His) is 732 a.a., with molecular weight of ~112 kDa.
C2/Complement C2 protein is essential in the classical pathway of the complement system. Activated by factor C1, C2 is cleaved into C2b and C2a. As a serine protease, C2a interacts with C4b, generating the C3 or C5 convertase. This crucial process activates and amplifies the complement cascade. C2/Complement C2 Protein, Human (HEK293, Fc) is the recombinant human-derived C2/Complement C2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of C2/Complement C2 Protein, Human (HEK293, Fc) is 732 a.a., with molecular weight of 110-130 kDa.
Complement C2 is a component of the classical pathway of the complement system and is cleaved by activated factor C1, resulting in the formation of two distinct fragments: C2b and C2a. The subsequent serine protease activity of C2a is critical for its subsequent interaction with the complement factor C4b, leading to the formation of C3 or C5 convertase. C2/Complement C2 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived C2/Complement C2 protein, expressed by HEK293 , with C-His labeled tag. The total length of C2/Complement C2 Protein, Cynomolgus (HEK293, His) is 732 a.a., with molecular weight of 90-110 kDa.
CFB is an important component of the alternative pathway of the complement system and is cleaved by factor D, producing two fragments: Ba and Bb. The Bb fragment is characterized as a serine protease and subsequently forms a complex with complement factor 3b, ultimately producing a C3 or C5 convertase. CFB Protein, Mouse (His) is the recombinant mouse-derived CFB protein, expressed by E. coli , with N-6*His labeled tag. The total length of CFB Protein, Mouse (His) is 739 a.a., with molecular weight of ~87 kDa.
The C5AR2 protein is a receptor for C3a, C4a, and C5a peptides as well as ASP/C3adesArg, C4adesArg, and C5adesArg, and is weakly coupled to G(i)-mediated signaling pathways. It interacts with C3 and exhibits higher affinity for the lipogenic hormone ASP. C5AR2 Protein, Human (Cell-Free, His) is the recombinant human-derived C5AR2 protein, expressed by E. coli Cell-free , with C-10*His labeled tag. The total length of C5AR2 Protein, Human (Cell-Free, His) is 337 a.a., with molecular weight of 38.9 kDa.
C5b-9 Antibody is an unconjugated, rabbit-derived, anti-C5b-9 polyclonal antibody. C5b-9 Antibody can be used for: WB, IHC-P, IHC-F, IF expriments in human, rat, and predicted: mouse background without labeling.
